The estimated Net Worth of Edward M. Md Kaye is at least $6.64 Million dollars as of 20 May 2024. Dr Kaye owns over 42,350 units of Stoke Therapeutics stock worth over $397,980 and over the last 12 years he sold STOK stock worth over $5,286,881. In addition, he makes $958,046 as CEO & Director at Stoke Therapeutics.
Sign up
Dr Kaye STOK stock SEC Form 4 insiders trading
Dr has made over 19 trades of the Stoke Therapeutics stock since 2015, according to the Form 4 filled with the SEC. Most recently he sold 42,350 units of STOK stock worth $653,461 on 20 May 2024.
The largest trade he's ever made was exercising 50,000 units of Stoke Therapeutics stock on 16 December 2019 worth over $30,000. On average, Dr trades about 4,898 units every 42 days since 2012. As of 20 May 2024 he still owns at least 27,000 units of Stoke Therapeutics stock.
You can see the complete history of Dr Kaye stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Dr. Edward M. Kaye biography
Dr. Edward M. Kaye is the CEO & Director at Stoke Therapeutics.
What is the salary of Dr Kaye?
As the CEO & Director of Stoke Therapeutics, the total compensation of Dr Kaye at Stoke Therapeutics is $958,046. There are 1 executives at Stoke Therapeutics getting paid more, with Stephen Tulipano having the highest compensation of $1,176,400.
How old is Dr Kaye?
Dr Kaye is 72, he's been the CEO & Director of Stoke Therapeutics since . There are no older and 20 younger executives at Stoke Therapeutics.
What's Dr Kaye's mailing address?
Edward's mailing address filed with the SEC is 350, Oyster Point Boulevard, South San Francisco, San Mateo County, California, 94080, United States.
Insiders trading at Stoke Therapeutics
Over the last 5 years, insiders at Stoke Therapeutics have traded over $49,612,288 worth of Stoke Therapeutics stock and bought 4,288,550 units worth $94,976,062 . The most active insiders traders include Group, Llc Green Jeremy Red..., Investments, Lpwong Roderic..., and Trust Blue Horizon Enterpri.... On average, Stoke Therapeutics executives and independent directors trade stock every 23 days with the average trade being worth of $1,639,987. The most recent stock trade was executed by Barry Ticho on 3 September 2024, trading 10,000 units of STOK stock currently worth $6,000.
What does Stoke Therapeutics do?
Stoke Therapeutics, Inc., an early-stage biopharmaceutical company, develops novel antisense oligonucleotide (ASO) medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary Targeted Augmentation of Nuclear Gene Output to design ASOs to precisely upregulate protein expression. Its lead clinical candidate is STK-001, which is in phase I/IIa clinical trial to treat Dravet syndrome, a severe and progressive genetic epilepsy; and STK-002, which is in preclinical stage for the treatment of autosomal dominant optic atrophy. It had entered into a license and collaboration agreement with Acadia Pharmaceuticals Inc. for the discovery, development, and commercialization of novel RNA-based medicines for the treatment of severe and rare genetic neurodevelopmental diseases of the central nervous system. The company was formerly known as ASOthera Pharmaceuticals, Inc. and changed its name to Stoke Therapeutics, Inc. in May 2016. Stoke Therapeutics, Inc. was incorporated in 2014 and is headquartered in Bedford, Massachusetts.
What does Stoke Therapeutics's logo look like?
Complete history of Dr Kaye stock trades at Cytokinetics Inc, Sarepta Therapeutics Inc, Avidity Biosciences, and Stoke Therapeutics
Stoke Therapeutics executives and stock owners
Stoke Therapeutics executives and other stock owners filed with the SEC include:
-
Stephen Tulipano,
Chief Financial Officer -
Dr. Edward M. Kaye,
CEO & Director -
Dr. Edward M. Kaye M.D., Ph.D.,
CEO & Director -
Huw Nash,
Chief Operating Officer, Chief Business Officer -
Barry Ticho,
Chief Medical Officer -
Edward Kaye,
Chief Executive Officer, Director -
Dr. Barry S. Ticho FACC, M.D., Ph.D.,
Chief Medical Officer -
Stephen J. Tulipano CPA, CPA, MBA,
Chief Financial Officer -
Seth Harrison,
Independent Chairman of the Board -
Jennifer Burstein,
Independent Director -
Adrian Krainer,
Independent Director -
Arthur Tzianabos,
Independent Director -
Arthur Levin,
Independent Director -
Dr. Adrian R. Krainer Ph.D.,
Co-Founder, Independent Director & Member of Scientific Advisory Board -
Garry Menzel,
Independent Director -
Julie Smith,
Independent Director -
Gene Liau,
Executive Vice President, Head of Research and Preclinical Development -
Dawn Kalmar,
Chief Communications Officer -
Jonathan Allan J.D.,
Deputy Gen. Counsel -
Dr. Gene Liau,
Chief Scientific Officer -
Dr. Huw M. Nash Ph.D.,
COO & Chief Bus. Officer -
Nancy M. Wyant,
VP & Head of Clinical Operations -
Shamim Ruff,
Chief Regulatory Officer -
Joan Wood,
Head of HR -
Isabel Aznarez Ph.D.,
Co-Founder, VP & Head of Biology -
Group, Llc Green Jeremy Red...,
-
Samuel W. Hall,
Director -
Life Science Ventures, L.P....,
-
Investments, Lpwong Roderic...,
-
Robin A. Walker,
Chief Legal Officer, CCO & Sec -
Jonathan Allan,
GENERAL COUNSEL & CORP SEC -
Trust Blue Horizon Enterpri...,
-
Thomas Leggett,
Chief Financial Officer -
Ian F Smith,